A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution

Breast

Volumn 15, Issue 6, 2006, Pages 728-735

  Crowe, Joseph P ^a   Patrick, Rebecca J ^a   Rybicki, Lisa A ^a   Escobar, Pedro F ^a   Weng, David ^a   Thomas Budd, G ^a   Tubbs, Raymond R ^a   Procop, Gary W ^a   Hicks, David G ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Data model; FISH; HER2; Survival; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER STAGING; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL;

EID: 33751180573     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.03.005     Document Type: Article

References (31)

1. Yeon C.H., and Pegram M.D. Anti-erb-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Investigational New Drugs 23 (2005) 391-409
2. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 (2001) 1-13
3. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
4. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 12 (1989) 707-712
5. Hicks D.G., and Tubbs R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36 (2005) 250-261
6. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 1 (2004) 1706-1716
7. Pegram M., and Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27 (2000) 13-19
8. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 (1999) 2241-2251
9. Remacle A., McCarthy K., Noel A., et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89 (2000) 118-121
10. Berx G., and van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3 (2001) 289-293
11. Fabi A, Ferretti G, Salesi N, et al. Can HER2 overexpression predict response to pegylated liposomal doxorubisin in metastatic breast cancer patients? Doi:10.1093/annonc/mdi078; 10 January 2005.
12. Del Mastro L., Bruzzi P., Nicolo G., et al. HER2 expression and efficacy of dose-dense anthracycline-containing chemotherapy in breast cancer patients. Br J Cancer 93 (2005) 7-14
13. Liu S., Lie W., Jakubczak J.L., et al. Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc Natl Acad Sci 99 (2002) 3770-3775
14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
15. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
16. Hicks D.G., Yoder B.J., Pettay J., et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplilfication: a fluorescence in situ hybridization study. Hum Pathol 36 (2005) 345-356
17. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti HER23 monoclonal antibody in women who have HER2-overexpressing metastatic breast disease. J Clin Oncol 17 (1999) 2639-2648
18. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
19. Tedesco K.L., Thor A.D., Johnson D.H., et al. Docetaxel combined with trastuzumab is an active regimen in HER2 3+ overexpressing and fluroescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trail. J Clin Oncol 22 (2004) 1071-1077
20. Ross J.S., Fletcher J.A., Linette G.P., et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
21. Tubbs R.R., Pettay J.D., Roche P.C., et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
22. Dowsett M., Bartlett J., Ellis J.O., et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199 (2003) 418-423
23. Press M.F., Slamon D.J., Flom K.J., et al. Evaluation of HER2 gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
24. Ridolfi R.L., Jamehdor M.R., and Arber J.M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13 (2000) 866-873
25. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
26. Perez E.A., Roche P.C., Jenkins R.B., et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77 (2002) 148-154
27. Yarden Y., and Sliwkowski M. Untangling the ErbB signaling network. Nat Rev/Mol Cell Biol 2 (2001) 127-137
28. Allred D.C., Clark G.M., Molina R., et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23 (1992) 974-979
29. Ho G.H., Calvano J.E., Bisogna M., et al. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 89 (2000) 2153-2160
30. Hoff E.R., Rubbs R.R., Myles J.L., et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 117 (2002) 916-921
31. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423